Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Novartis Plans to Acquire Biotech Firm Excellergy for Up to USD2 Billion
Recommend 3 Positive 2 Negative 0 |
||||
|
||||
|
Novartis plans to acquire the biotech firm Excellergy for up to USD2 billion. The transaction is expected to be completed in the second half of this year, subject to various conditions, including regulatory approval. The acquisition agreement will include an initial payment and milestone payments. Through this transaction, Novartis will acquire Excellergy's candidate drug Exl-111, an anti-IgE antibody currently in early testing stages, which will complement the company's existing allergy product portfolio. (mn/j) AASTOCKS Financial News Website: www.aastocks.com Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
|
||||
Copied to Clipboard
 |
||||
